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ABSTRACT 
Medulloblastoma is the most common malignant pediatric brain cancer and is 
classified into four different subgroups based on genetic profiling: sonic hedgehog (SHH), 
WNT, Group 3 and 4. Changes in gene expression often alter the progression and 
development of cancers. One way to control gene expression is through the acetylation and 
deacetylation of histones. More specifically in medulloblastoma SHH and Group 3, there 
is an increased deacetylation, and histone deacetylase inhibitors (HDACi) can be used to 
target this change. Not only can HDACi target increases in deacetylation, they are also 
known to induce cell cycle arrest and apoptosis. The combination of these factors has made 
HDACi a promising cancer therapeutic. Panobinostat, a hydrophobic, small molecule 
HDACi was recently identified as a potent molecule of interest for the treatment of 
medulloblastoma. Furthermore, panobinostat has already been FDA approved for 
treatment in multiple myeloma and is being explored in clinical trials against various solid 
tumors. The laboratory is interested in developing strategies to encapsulate panobinostat 
within nanoparticles composed of the biodegradable and biocompatible polymer 
poly(lactic acid)-poly(ethylene glycol) (PLA-PEG). Nanoparticles are formed by single 
emulsion, a process in which hydrophobic drugs can be trapped within the hydrophobic 
nanoparticle core.  The goal was to determine if the molecular weight of the hydrophobic 
portion of the polymer, PLA, has an impact on loading of panobinostat in PLA-PEG 
nanoparticles. Nanoparticles formulated with PLA of varying molecular weight were 
characterized for loading, size, zeta potential, controlled release, and in vivo tolerability. 
The results of this work demonstrate that panobinostat loaded nanoparticles are optimally 
formulated with a 20:5kDa PLA-PEG, enabling loading of ~3.2 % w/w panobinostat within 
nanoparticles possessing an average diameter of 102 nm and surface charge of -8.04 mV. 
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Panobinostat was released from nanoparticles in a potentially biphasic fashion over 72 
hours. Nanoparticles were well tolerated by intrathecal injection, although a cell culture 
assay suggesting reduced bioactivity of encapsulated drug warrants further study. These 
experiments demonstrate that the molecular weight of PLA influences loading of 
panobinostat into PLA-PEG nanoparticles and provide basic characterization of 
nanoparticle properties to enable future in vivo evaluation.  
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1. INTRODUCTION 
 
Medulloblastoma is the most common malignant pediatric brain tumor with a peak 
diagnosis between the ages of six and eight years old. Standard treatment includes 
maximum safe resection and subsequent radiation and chemotherapy. Although the overall 
5- year survival is approximately 80%, the neuroendocrine, neurological and psychological 
damage from the aggressive treatment leave patients with long-term health complications. 
Thus, researchers and clinicians are focused on finding a treatment that can reduce or 
eliminate these toxicities while improving the overall survival and quality of life. (30,40).   
At the molecular level, medulloblastoma is classified into four subtypes: WNT, sonic 
hedgehog (SHH), Group 3 and Group 4. Each of these subtypes are associated with distinct 
genetic aberrations (29). Deregulated expression of genes is associated with development 
of tumors due to impaired control of differentiation and the cell cycle. One of controlling 
expression is through the modifications of histones (37). One of the best characterized 
modifications, histone acetylation, is mediated by histone acetyltransferase (HAT) and 
histone deacetylases (HDAC). Increased deacetylation is known to play a role in SHH and 
group 3 subgroups of medulloblastoma, and histone deacetylase inhibitors (HDACi) have 
been used to target this change (4,29,33,39). Furthermore, HDACi are known to induce 
cell cycle arrest and apoptosis and sensitize tumor cells to radiation and chemotherapy 
(29,44).  
Although the approach of HDACi has shown preclinical and clinical efficacy for 
hematological cancers (27), their efficacy has largely been limited when applied to treating 
solid tumors (37). However, panobinostat, a hydrophobic HDACi, has be identified as a 
potential candidate against both hematological and solid tumors (6,14,31,42). Research 
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conducted at Sanford Burnham Prebys Medical Discovery Institute by Dr. Robert 
Weschler-Reya showed in a high-throughput screen against medulloblastoma human and 
murine group 3 cells that panobinostat potently inhibited growth and was effective against 
all medulloblastoma subgroups. However, in a preclinical in-vivo study panobinostat did 
not significantly increase survival when tolerable doses of panobinostat were administered 
to mice with xenograft of diffuse pontine glioma (DIPG) (17). The inconsistency of 
panobinostat can possibly be attributed to poor delivery to solid tumors, which have 
complex and abnormal vasculature that limits drug perfusion (20).  
However, using panobinostat as a therapy for intrathecal administration poses a few 
problems. Panobinostat is poorly soluble and thus delivery of the drug safely to the central 
nervous system is difficult. Currently there are two market products of panobinostat: 
Farydak’s oral capsule and Midatech’s solubilized panobinostat through their 
nanoinclusion technology. While Farydak developed a delivery mechanism, severe 
diarrhea occurred in 25% of patients, and cardiac toxicities are associated with the drug 
(1,4). Midatech Pharma developed MTX110, a formulation that solubilizes panobinostat 
with their proprietary nano-inclusion technology (2). This compound is currently being 
used in clinical trials to treat DIPG through convection enhanced delivery (9). While 
MTX110 provides a means to solubilize panobinostat without toxic solvents, it does not 
fully address the problems of short drug half-life and high toxicity.  Efforts are also 
underway to encapsulate panobinostat into nanoparticles. Choi et al. have been able to load 
PLGA particles with panobinostat with the goal of treating T-cell leukemias (5).  
Nanoparticles are known to tackle limitations of free drug (pharmacodynamic, release 
and toxicity issues) by providing the drug with a modifiable carrier. Free drug formulations 
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tend to have a short half-life, whereas nanoparticle-encapsulated formulations can maintain 
the drug concentration in the location of the tumors, effectively killing tumor cells (19,34). 
Extended-release nanoparticles can be help overcome delivery limitations of freely 
administered drug by providing a mechanism to control the release of the encapsulated 
drug and target the tumor. Various carriers exist, however the most commonly used are 
biodegradable polyesters like PLGA and PLA.  Polymeric nanoparticles provide several 
benefits, including customizable surface modifications for targeting and especially 
improved payload tolerability. For example, camptothecin-loaded PLGA has improved 
tolerability of camptothecin and improved survival of mice with orthotopic gliomas in mice 
compared to free camptothecin alone (18).  
In addition to the polymer identity, the molecular weight of the polymer or material for 
carrier can affect the release mechanisms (11,13,16, 21, 24, 34, 37, 46). As reviewed in 
Kamaly et al., molecular weight affects the degradation rate such that lower molecular 
weight polymers degrade more rapidly compared to higher molecular weight polymers. 
Moreover, lower molecular weight polymers produce particles of smaller sizes, which can 
be relevant to biological processes, since smaller particles remain in circulation for longer 
(20).  
Nanoparticles may be loaded in two ways: first, the drug may enter the particle and be 
held inside the particle, or second, the drug may associate with the surface of the particle. 
While prior studies in the lab showed that quisinostat, an HDACi, was maximally loaded 
into PLA-PEG nanoparticles via surface association (19), additional studies suggested that 
surface loading was not an effective fabrication strategy for producing panobinostat PLA-
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PEG nanoparticles. We were therefore motivated to determine conditions under which 
panobinostat would load effectively into the core of nanoparticles. 
In this study, we present an attempt to understand the factors that influence loading of 
PLA-PEG nanoparticles with panobinostat. We hypothesized that increasing molecular 
weight of PLA would enhance loading of panobinostat into the core of the nanoparticle. 
We further predicted that molecular weight and hydrodynamic size will be correlated, as 
previously described by Govender and Kamaly, and that size will increase as the molecular 
weight increases (15, 21).  
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2. MATERIALS AND METHODS 
2.1 Materials 
 
Panobinostat (LBH-589) was obtained from APExBIO (Houston, TX, USA). Poly(d, 
l-lactide)-b-methoxy poly(ethylene glycol) (PLA-mPEG) was purchased from 
PolySciTech (West Lafayette, IN USA) with varying molecular weights (PEG: PLA; 
~5000 : 14kDa, 16kDa, 18kDa, 20kDa, 35kDa). HyClone endotoxin free water (<0.005 
EY/mL) was purchased from Fisher Scientific (Pittsburg, PA USA) and was used 
throughout the nanoparticle fabrication process. Dichloromethane (DCM), dimethyl 
sulfoxide (DMSO), sodium cholate and 10x phosphate buffered saline were purchased 
from Fisher Scientific (Pittsburg, PA USA). Dulbecco’s modified Eagle medium (DMEM), 
fetal bovine serum (FBS), 0.25% trypsin-EDTA were purchased from Gibco Invitrogen 
(Carlsbad, CA, USA). Greiner T25 tissue culture flasks with filter cap and Costar 96-well 
assay plates were purchased from VWR International (Radnor, PA, USA). Beetle luciferin 
(potassium salt) and CellTiter-Glo Luminescent Cell Viability Assay were purchased from 
Promega (Madison, WI, UAS). 
2.2 Nanoparticle Fabrication 
 
Nanoparticles were fabricated using a modified single emulsion technique as 
previously reported (19,20,28). A schematic of the process is shown in Figure 1. PLA-PEG 
(50 mg) was dissolved in DCM (2 mL). Panobinostat (5 mg) was dissolved in 300 μL of 
DMSO and added to the polymer solution. The polymer and drug solution were then added 
dropwise to 4 mL of 1% (w/v) sodium cholate while vortexing. The solution was then probe 
sonicated 3 times in 10 second bursts at 40% amplification over ice. The resulting emulsion 
was added to 20 mL of 0.1% (w/v) of sodium cholate and then left gently stirring for 3 
hours to allow the DCM to evaporate. After 3 hours the particles were washed and 
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concentrated using an Amicon Ultra-15 Centrifugal Filters (100 kDa cut-off) for 3, 20 min 
spins at 5000 RCF. Particles were aliquoted and lyophilized to determine their 
concentration and loading. The remaining particles were kept frozen at -80°C for storage. 
 
Figure 1:  Schematic of nanoparticle fabrication process 
 
 
2.3 Nanoparticle Characterization 
 
2.3.1 Drug Loading 
 
Lyophilized particles were dissolved in DMSO to achieve a concentration of 5 mg/mL. 
Samples were plated in triplicate (40 μL of particles and 10 μL of DMSO) on a clear, flat-
bottomed 96 well plate. The standard curve was determined using 40 μL of blank particles 
in each well, adding 10 μL of panobinostat at known concentrations to achieve a total 
volume of 50 μL. A total of 9 concentrations were used in the range. The loading was then 
quantified by absorbance (290 nm) using BioTek reader and the Gen 5 software. The 
loading was calculated as the mass of panobinostat divided by the mass of polymer (w/w 
%). 
2.3.2 Size and Zeta Potential 
 
The hydrodynamic size and zeta potential of the particles were measured using 
NanoBrook 90Plus Zeta (Brookhaven Instruments, Holtsville, NY USA). Nanoparticles 
were suspended at a concentration of 1 mg/mL in sterile filtered 1 mM KCl. 
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2.3.3 Controlled Release 
 
To determine the release profile of panobinostat, a protocol from Wang et al (43) was 
adapted. Nanoparticles were diluted to a concentration of 1 mg/mL and 400 μL was added 
to a 3.5 k MWCO Slide-A-Lyzer Dialysis cassette (Thermo Fisher Scientific, Waltham, 
MA USA). The cassettes were then submerged in 4L of PBS maintained at 37 °C (pH 7) 
with gentle stirring. The PBS was refreshed after 6 hours, 12 hours and every 12 hours 
after. At each time point, samples (30 μL) were removed from the cassette. Samples were 
placed in a clear, flat bottomed 96 well plate and read by absorbance as described in 2.3.1. 
 
2.4 In-vitro Study 
 
2.4.1 Cell Culture 
 
GL261 cells were grown in T25 tissue culture flasks in DMEM with 10% FBS at 37 
°C and 5% CO2. To collect cells for passaging or counting, media was removed and 
replaced with 1 mL 0.25% trypsin-EDTA. The flask was tapped and shaken to help cells 
detach. To quench the trypsin-EDTA, 1 mL of media with 10% FBS was added. The cells 
were centrifuged at 800 RPM for 6 minutes and resuspended in 3 mL of media containing 
10% FBS.  The Cellometer mini (Nexcelom Bioscience, Lawrence, MA, USA) was used 
to count cells prior to in vitro experiments. 
 
2.4.2 Measurement of Panobinostat Activity 
 
GL261 cells were seeded on a 96-well clear-bottomed, white-walled plate with a 
density of 3000 cells/well in 100 μL of media. The cells were left to incubate and adhere 
to well for 4 hours prior to treatment. Each plate was treated with 10 μL/well of 17 serial 
dilutions (1:2) of panobinostat nanoparticles or free drug, which generated concentrations 
  
8 
in the wells between 0.5 mM and 8 μM. DMSO and drug empty nanoparticles were used 
as vehicle controls. PBS were used as the negative control. After 72-hour incubation, cell 
viability was determined using CellTiter-Glo.  An IC50 value was calculated in GraphPad 
Prism 8 (San Diego, CA USA) by a nonlinear fit of the log (inhibitor) vs. response function. 
 
2.5 In-vivo Tolerability 
 
All procedures and animal care practices were performed in accordance with the 
University of Texas Health Science Center’s Institutional Animal Care and Use 
Committee. To determine the maximum tolerated dose (MTD) of panobinostat 
nanoparticles, incremental doses were administered via intracisternal injection to 
C57BL/6J mice. Mice were anesthetized with isoflurane during the duration of the surgery 
and mounted on a stereotactic frame (Kopf Instruments, Tujunga, CA, USA) using 
HotHands (KOBAYASHI, Dalton, GA, USA) hand warmers to maintain temperature of mice. 
Animals were given buprenorphine SR and bupivacaine subcutaneously for pain 
management. The animal’s head was shaved and sterilized with three alternating passes 
each of betadine and ethanol. An incision was made from middle of the head in rostral- 
caudal direction, 1 cm. Using soft tissue scissors and forceps, the membrane was removed 
that covers the skull and cerebellar regions. Using hemostats, muscles were retracted to 
expose the cisterna magna, and a Hamilton syringe loaded with 2 μL of nanoparticles at 
the required drug concentration was inserted into the cisterna magna at a depth of 1.5 mm. 
After 1 minute, the syringe was pulled up to 1mm and the nanoparticles were injected over 
2 minutes controlled using a syringe pump 11 elite nanomite (Harvard apparatus, Holliston, 
MA, USA). One-minute post infusion, the syringe was removed, and the incision was 
closed using staples. Mice were placed in a clean cage post-surgery to wake up from 
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anesthesia and were observed for 3 hours post-surgery for any acute reaction to drug. 
Weights were obtained daily for 3 days to determine tolerability of the drug. Euthanasia 
was performed if animals lost more than 15% post-surgery or if humane endpoints were 
reached. Humane endpoints include: significant motor deficits, reduced splay of limbs 
when animal is lifted, vocalization, and lethargy.  
 
2.6 Statistical Analysis 
 
Statistical analyses were performed with GraphPad Prism 8 software. The Pearson 
correlation coefficient was first measured to assess the strength of any possible 
relationships. Then a linear regression using least squares was conducted to determine if 
these relationships could be explained by a linear model. An unpaired two-tailed t-tests 
with Welch’s correction was utilized to determine significance of loading between particles 
made with different molecular weights. Significance thresholds used include p < 0.001 
(***), p < 0.01 (**), and p < 0.05 (*).   
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3. RESULTS 
 
 The molecular weight values referenced in this report refer to the product labels 
provided by PolySciTech. However, there are differences in the molecular weight and 
weight number that the global product classification (GPC) standard testing reports (3). 
The molecular weight reported for the PLA are based on the molecular numbers that the 
GPC analysis provided. The 14kDa and 18kDa molecular weights are significantly 
different from their molecular number. The polymers with 20 kDa and 35kDa have 
molecular numbers closer than reported. Overall, the polydispersity for these polymers is 
also greater than 1.5, thus the weight average is near double the number average.  
Table 1:  Molecular weight and number are the GPC reported values for the PLA used to 
produce the various formulations of nanoparticles. 
 
The following analysis between molecular weight, size, zeta and percent loading are 
based on the molecular number and molecular weight.  
3.1 Nanoparticle Loading and Characterization 
 
Diameters of nanoparticles ranged from 84 to 130 nm with the average polydispersity 
index among all batches and molecular weights being 0.11. The particles with the smallest 
size were made with 16,640:5000 Da PLA-PEG and the particles that were the largest was 
made out of 358080:5000 Da. There is a strong correlation between molecular weight and 
the hydrodynamic size with the Pearson’s correlation coefficient r= 0.89. Furthermore, the 
slope is significantly different than 0, with the adjusted R squared value of 0.78, meaning 
Molecular 
Weight (Da) 
Number Average Molecular 
Weight (Da) 
Weight Average Molecular 
Weight (Da) 
14,000 16640 30226 
18,000 23644 66613 
20,000 28427 43369 
35,000 35808 65506 
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that 78% of the variability in size can be described by the linear relationship (Figure 2A). 
The residual plot in B further confirms that the linear relationship is a good model to 
describe the data as the residuals do not follow a pattern (Figure 2B).  
Furthermore, it was predicted that there would be a correlation between molecular 
weight and percent loading.  The particles made with 23644: 5000 Da PLA: PEG loaded 
the least, with an average loading of 0.42% w/w, and the particle with the molecular weight 
of 28427:5000 Da PLA: PEG with an average loading of 3.16%. Interestingly, the particle 
made with the lowest molecular weight (16,640:5000 Da PLA: PEG) had a significantly 
greater loading than the (23644: 5000 Da PLA: PEG) (Figure 3). Furthermore, there is a 
significant jump between 23644: 5000 Da PLA: PEG and 28427:5000 Da PLA: PEG 
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Figure 2: (A) The relationship between molecular weight (Da) and hydrodynamic size 
(nm) with a Pearson’s coefficient r = 0.89, the line of best fit is represented on the graph 
with a slope of 0.002 (B) Represents the residuals from (A). (C) The relationship 
between molecular weight (Da) and percent loading (nm) with a Pearson’s coefficient 
of r = 0.75 (D) Represents the residuals from (C)                                                                                                                                                                                                                                                
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Figure 3: Particle A- 16640 Da PLA, Particle B- 23644 Da PLA, Particle C- 28427 Da 
PLA, Particle D- 35808 Da PLA. When treated as a categorical variable, we see that 
particle A load significantly more than particle B (p = 0.037 < 0.05), but significantly less 
than particle C and D (p = 0.00023 < 0.001), which were roughly equivalent in loading (p 
= 0.63 > 0.05).   
 
 
Furthermore, the molecular weight and encapsulation efficiencies mirror the 
relationship between molecular weight and percent loading. The particles made with the 
lower molecular weights had a lower encapsulation efficiency while the particles made 
with the larger molecular weight PLA had a greater encapsulation efficiency (Table 2). 
However, all encapsulation efficiencies were less than 50%. Thus, a significant portion of 
drug was not encapsulated and must have been lost during the fabrication process. 
 
Table 2: Encapsulation efficiencies for particles of drug based on the molecular weight of 
the PLA. 
 
Molecular 
Weight (Da) 
Number Average Molecular 
Weight (Da) 
Encapsulation Efficiency (%) 
14,000 16640 9.38 
18,000 23644 4.15 
20,000 28427 31.6 
35,000 35808 30.2 
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Surface charge governs how nanoparticles interact with cells and proteins. Thus, we 
assessed zeta potential of each nanoparticle formulation.  
 
 
Figure 4: (A) The Pearson’s Correlation Coefficient between molecular weight and zeta 
shows no positive or negative correlation (r= 0.28). (B) The Pearson’s Correlation 
Coefficient between loading and zeta potential shows no correlation (r= 0.26)   
 
Zeta potential (mV) ranged between -4.3 and -8.9 mV. The particle made with 16,640:5000 
Da PLA: PEG had the most negative potential (-8.8mV), and the particle made with 
28427:5 Da PLA: PEG had the most neutral potential (-4.3mV). There is no linear 
correlation between molecular weight and zeta potential, as there is no significance in the 
slope from slope of 0 (p=0.57 > 0.05). Particles with molecular weights 16,640, 23644 and 
35808 Da PLA had the most variability in the zeta potential between particle batches, with 
standard deviations of 3, 3.4, and 5 respectively.  As zeta potential can be indicative of 
loading location, the relationship between to variables was also assessed. There is no strong 
correlation between loading and zeta potential r= 0.26 furthermore the slope is not 
significantly greater than 0 (p=0.07> 0.05). 
The following sections will present the time-dependent release characteristics, in-
vitro activity, and in-vivo tolerability of 20:5 kDa PLA-PEG encapsulated panobinostat 
particles.  We chose to further investigate and characterize this particle because it 
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demonstrated the highest average loading in the earlier studies. Furthermore, the zeta 
potential was less variable and the yield of these particles were more consistent.  
3.2 Release Characteristics  
 
The release of panobinostat from the particles was measured for a total of 72 hours. 
During the 72-hour period, 88% of the loaded drug was released from the particles. The 
release profile may be divided into three distinct phases. In the first period (period A), 
which lasted 6 hours, there was a rapid release of 55% of the drug. In the second period 
(period B), which occurred between 6 and 12, there was a slight plateau in the drug’s 
release. Only a total of 59% of the drug was released by the end of period B, indicating that 
only 4% of the drug had been released over these 6 hours. Over the next 60 hours which 
comprised period C, the remaining 29% of the drug was released. During period C there 
was initially a period where there was more rapid release of the drug than in period B, after 
which the drug release plateaued. Thus, the release profile may be generally characterized 
as biphasic, with a period of relative diminished release in between the two release phases.  
This was seen in both experimental replicates, which were different batches of particles.  
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Figure 5: 28427:5 kDa PLA-PEG encapsulated panobinostat reveals a biphasic release profile 
over the course of 72 hours to release a total of 88% of the encapsulated drug (n=2). 
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3.3  In-vitro Panobinostat activity 
 
To determine if the activity of panobinostat had been maintained after encapsulation, 
a cell viability assay was conducted as described in 2.4.2. If activity is maintained the 
concentration drug to kill half the cells would be equivalent or less for particles compared 
to free drug. Equivalent concentrations of drug were tested starting at 0.5mM. Blank 
particles were used for no drug. The nanoparticle IC50 was 177 nM. However, the free 
drug appeared to kill a significant portion of the cells at all concentrations tested due to an 
excess of DMSO solvent, and an accurate IC50 could not be determined.  
 
 
Figure 6: n=3 In vitro panobinostat-loaded nanoparticle efficacy against GL261. Three 
different batches of nanoparticles were used as a treatment. 100% cell survival is based on 
the negative control (PBS) and 0% cell survival is based on the blank particle control.  
 
Between the treatments (different batches of particles) are different and thus leading to 
the large standard deviation.  After determining the in-vitro toxicity of the particles, the 
next step was to determine the tolerability of the particles after an intrathecal injection. 
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3.4 In-vivo tolerability  
 
Panobinostat from the nanoparticles was observed to kill GL261 cells, therefore in- 
vivo tolerability was investigated. The highest dose administered to the mice via cisterna 
magna injection, is 20 ug equivalent to the highest dose in the in vitro study. Overall within 
the first 3 days, the mice regained weight to pre-surgical weight. However, mouse 3 given 
4.6 ug took more time to regain weight. Initial weight loss is due to surgery.  
 
Figure 7: Maximum tolerated dose study on C576J black mice, with intracisternal 
injection. A loss of more than 12% indicates low tolerability. None of the mice lost more 
than 12% of body weight. Within 3 days post-surgery a majority of the animals 
(excluding M3) began to regain weight. 
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4. DISCUSSION 
 
As the interest in developing HDACi- based therapeutics for treating cancer growing, 
improving delivery is an important step in enhancing efficacy, reducing toxicities, and 
developing targeted strategies for cancer treatment. Treating solid tumors with free drug 
formations have been challenging due to the complex vasculature and hindrance from 
extracellular matrix. Nanoparticle formulations provide a promising avenue forward to 
deliver precise doses of a drug to its desired location. To achieve nanoparticle delivery, 
drugs must be effectively encapsulated.  Many factors are likely at play, including 
molecular size, hydrophilicity/hydrophobicity, surface charge, and physicochemical 
properties of both the drug and the polymer. By characterizing the relationship between 
these parameters, we sought to find factors that would increase the loading of panobinostat 
in PLA-PEG nanoparticles. 
Prior studies in the lab had focused on encapsulating another HDACi, quisinostat, in 
PLA-PEG nanoparticles by exploiting alkaline solutions to increase the loading of the drug 
up to 9% w/w. However, preliminary studies with panobinostat failed to show the same 
increases in loading with changes in pH. Furthermore, while quisinostat must be added at 
the evaporation phase to achieve maximal loading, panobinostat may be added to the 
organic phase, suggesting differences in the way that the two drugs load into PLA-PEG 
nanoparticles (19). The molecular weight of the copolymer was investigated for two 
reasons as a factor that might enhances drug encapsulation. First, molecular weight 
increases the size of a particle, potentially providing more “room” for the drug, and second, 
molecular weight has been shown to impact the release of the drug (11,13,16, 21, 24, 34, 
37, 46).  
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However, we did not find a strong correlation between molecular weight and loading. 
This does not preclude the possibility that molecular weight still has some effect on 
loading. We did observe that the highest molecular weights (28427 Da and 35808 Da PLA) 
had the highest average loading, which suggests that maybe higher molecular weight 
particles do in fact have a higher drug capacity. Interestingly, the 23644 Da PLA particle 
had significantly lower loading than the 16640 Da particle, which suggests that other 
factors are at play. Perhaps increases in molecular weight do not generate increases in 
capacity. This could be due to differences in internal structure that were not assayed, and 
may be an avenue of future investigation through transmission electron microscopy. Rather 
than increased capacity, as the size of these particles do not greatly change to be directly 
associated with more loading, it may be the interaction of the drug and polymer. Generally, 
improving the solubility of drug in the hydrophobic core of a polymeric particle will 
increase its loading. Thus, the higher molecular weight PLA was able to increase the 
loading of panobinostat by improving its solubility in this core. A similar relationship was 
noticed with another co-polymer methoxy poly (ethylene oxide)-block- poly(ε-
caprolactone) (PEO-b-PCL). The longer chains of PCL were able to increase the loading 
of amiodarone, a more amphiphilic drug (48). Panobinostat interacting with the longer PLA 
chain lengths in the 28427 Da and the 35808 Da PLA particles, increased its loading. 
However, it is interesting to note that the loading was not strongly correlating with 
molecular weight, as the particles made with the lowest molecular weight (16640 Da) did 
have a higher loading than the 23644 Da particle. While it was expected that the 23644 Da 
PLA: PEG would have a higher loading, since it is the longer PLA chain, there may be 
other factors that contributed to a lower loading in those particles. That potentially that 
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specific ratio of PLA:PEG may not have contributed to a favorable interaction with the 
panobinostat.  
Another important piece of information was the encapsulation efficiency of these 
particles was all less than 50%. Again, this establishes that potentially the interaction 
between the panobinostat and PLA: PEG may not have been as favorable thus 
encapsulating less efficiently. As expected particles that had lower percent loadings also 
had significantly lower encapsulation efficiencies. Other factors would need to be 
investigated such as the solvent for the single emulsion technique and the polymer itself 
having an impact on how the drug is encapsulating.  
A further characterization of particles made with 28644 Da PLA displayed some 
interesting characteristics of these particles. First the particles displayed a biphasic release 
profile. Secondly the drug was tolerable at higher doses, which could be attributed to the 
decrease in bioactivity of panobinostat loaded in these particles.   
The biphasic release profile seen was that a majority of the drug released in the first 6 
hours, a plateau where little drug was released over the next 6 hours, and a final phase 
where the remainder of the drug was released over the next 60 hours. This again points to 
an interaction between the drug and the polymer. Xiao et al. described that the ratio 
between PLA and PEG has a major impact on the release characteristics of the particle 
(39). This could because there is a significant interaction between the PLA and 
hydrophobic drugs. Yang et al. observed this phenomenon when they noted that insoluble 
Amphotericin B interacted with the hydrophobic PLA element of the nanoparticle (46). 
They additionally found that the drug close to the surface is released fastest, with the 
remainder of the drug at the interior diffusing out more slowly over the course of 80 hours. 
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As the higher molecular chains did have an interaction with the drug therefore solubilizing 
panobinostat more effectively in the hydrophobic core, the drug was able to release slower. 
However, we were not able to compare the release of these particles to the formulations 
made with other PLA lengths as concentrating the particles reduced the polydispersity of 
these particles. Furthermore, in order to accurately collect the release data, an initial high 
drug concentration is required and thus for the lower loading particles, achieving a high 
concentration is crucial.   
In order to determine the potency of the encapsulated panobinostat cell viability assays 
were conducted. However, while investigating there were a few roadblocks. As 
panobinostat is poorly soluble, 100% DMSO was used to dissolve to the required 
concentration 5 mg/ml. However, after 72 hours, when the free drug 96-well plate was 
read, the cell death was observed at lower drug concentrations including no drug and the 
DMSO vehicle control. It is inconclusive whether the free drug or DMSO is killing the 
cells especially at low concentrations of drug. While concentrations of DMSO above 10% 
are known to be cytotoxic to cells, the exact threshold for toxicity depends on the cell type 
(12,42). While these roadblocks were faced, IC50 data from Pei et al suggests that the 
encapsulation of panobinostat in this study may have reduced the bioactivity of the drug. 
The IC50 for panobinostat was 10nM against the murine group 3 medulloblastoma cell line 
(33). This is significantly less than 177 nM observed in this study. It is important to note, 
that between replicates of this experiment there are concerns over the accuracy of this IC50. 
First, the raw data and the variability between the replicates makes it difficult to determine 
if the average IC50 data is representative of the potency of these particles.  
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This bioactivity data provides some insight into reasons why the intrathecally 
administered nanoparticles were tolerable in mice at higher doses. Since the drug may not 
be as potent as free drug, the tolerability may have improved in the encapsulated drug only 
due to reduced potency. Currently these particles have been administered at a dose of 20 
ug without any toxic effects such as acute neurological symptoms and weight loss. This 
was the highest deliverable dose as the concentration of the particles and the volume of 
infusion were limiting factors. The major limiting factor in administering drug to the 
central nervous system with the intracisternal injection is making sure that the intracerebral 
pressure is not acutely increased. It is possible that a maximum tolerated dose may not be 
determined however, more studies will be conducted to deliver greater than 20ug. Future 
studies will use the maximum tolerated dose to explore if the formulation is effective at 
increasing overall survival of mice with medulloblastoma metastasis.  
There are a few steps that will be conducted for this research moving forward. First 
more cell viability assays need to be conducted to determine a more accurate IC50. 
Furthermore, reducing the concentration of DMSO and changing the vehicle to solubilize 
panobinostat will provide a direct comparison for the IC50 of panobinostat nanoparticles. 
As the encapsulation efficiency of panobinostat was low, potentially changing the drug and 
polymer ratios, solvent and the polymer are other factors that may impact and increase the 
efficiency of encapsulation. Finally, improving the concentrations of particles while 
maintaining a monodisperse particle solution to conduct more release profiles as molecular 
weight is also known to impact the release of the drug.  
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